Abstract Library

#4629 Identification of putative master regulators in pancreatic neuroendocrine tumours using gene expression data and network inference

Introduction: Pancreatic neuroendocrine tumours (pNETs) are a heterogenous group of pancreatic malignancies with a unique biology and pathophysiology. Tumour grade and extension are commonly used for prognostic determination. Current pathologic grading system needs regular updates to refine prognostic classification. Genomic screening may provide more objective classes and reflect tumour biology.

Conference:

Presenting Author: Jannin A

Authors: Jannin A, Elati M, Do Cao C, Figeac M, Leteurtre E,

Keywords: pancreatic neuroendocrine tumour, RNA-Seq, Master regulators, MEN1,

#4163 Metabolite biomarker discovery for pancreatic neuroendocrine tumors using metabolomic approach

Introduction: Metabolic flexibility is one of the key hallmarks of cancer and metabolites are the final products of this adaptation, reflecting the tumors’ aberrant changes. However, the metabolic plasticity of pancreatic neuroendocrine tumors (pNET) is still unknown. pNETs are heterogeneous which makes their diagnosis, prognosis and therapeutic management difficult.

Conference:

Presenting Author:

Authors: Jannin A, Dessein A, Dabo S, Descat A, Vantyghem M,

Keywords: pancreatic NET, diagnostic biomarker, plasma metabolites, molecular pathways,

#4139 Characterisation of new biomarkers from patients with neuroendocrine cancer using liquid biopsy methods

Introduction: Neuroendocrine tumors originate from neuroendocrine cells. Clinicians diagnose and track these tumors not only but also by analysing patients' blood for biomarkers. Including liquid biopsy in early detection and monitoring can improve patient outcomes.

Conference:

Presenting Author:

Authors: Pachnikova G, Jann H, Tacke F, Keilholz U,

Keywords: liquid biopsy, circulating tumor cells, cell-free DNA, neuroendocrine tumor, case study, copy number variations,

#3259 Treatment outcomes of patients with G3 neuroendocrine neoplasms

Introduction: Extrapulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia that are associated with a limited prognosis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Jann H, Wiedenmann B, Tacke F, Roderburg C,

Keywords: NEN G3, chemotherapy, Cisplatin, Carboplatin,

#3244 Efficacy and safety of immune checkpoint inhibitors in patients with neuroendocrine neoplasia: Report of a case series from a large tertiary centre

Introduction: Immune checkpoint inhibitors (ICI) have changed our view on how to treat cancer. Despite their approved treatment of many different cancers, efficacy of ICI in neuroendocrine neoplasia is limited and poorly understood. Established treatment options of neuroendocrine tumors (NET) and carcinomas (NEC) are based on surgery, tumor-targeted medical treatments, peptide guided radioreceptor therapy (PRRT) and locoregional therapies. However, in many patients these treatments lose efficacy over time, and novel therapies are urgently needed.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Özdirik B, Jann H, Tacke F, Wiedenmann B, Roderburg C,

Keywords: checkpoint inhibitor, neuroendocrine neoplasia, PD-L1,